NO20084882L - Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on - Google Patents

Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on

Info

Publication number
NO20084882L
NO20084882L NO20084882A NO20084882A NO20084882L NO 20084882 L NO20084882 L NO 20084882L NO 20084882 A NO20084882 A NO 20084882A NO 20084882 A NO20084882 A NO 20084882A NO 20084882 L NO20084882 L NO 20084882L
Authority
NO
Norway
Prior art keywords
crystalline forms
ribofuranosyl
thiazolo
pyrimidin
acetyl
Prior art date
Application number
NO20084882A
Other languages
English (en)
Inventor
Michael Mutz
Casper Vogel
Original Assignee
Anadys Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38287962&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20084882(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Anadys Pharmaceuticals Inc filed Critical Anadys Pharmaceuticals Inc
Publication of NO20084882L publication Critical patent/NO20084882L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/24—Heterocyclic radicals containing oxygen or sulfur as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Saccharide Compounds (AREA)

Abstract

Oppfinnelsen angår et maleatsalt av 5-amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d]pyrimidin-2-on og krystallinske former derav, fremstilling og anvendelse av dem, samt farmasøytiske preparater inneholdende disse krystallinske former.
NO20084882A 2006-05-22 2008-11-20 Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on NO20084882L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80242506P 2006-05-22 2006-05-22
PCT/EP2007/054899 WO2007135134A1 (en) 2006-05-22 2007-05-21 Crystalline a and b forms of a maleate salt of 5-amino-3- (2 ', 3 '-di-o-acetyl-beta-d-ribofuranosyl) -3h-thiaz0l0 [4, 5-d] pyrimidin-2-one

Publications (1)

Publication Number Publication Date
NO20084882L true NO20084882L (no) 2008-12-17

Family

ID=38287962

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084882A NO20084882L (no) 2006-05-22 2008-11-20 Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on

Country Status (15)

Country Link
US (1) US20100286081A1 (no)
EP (1) EP2027139A1 (no)
JP (1) JP2009537603A (no)
KR (1) KR20090029730A (no)
CN (1) CN101528762A (no)
AR (1) AR061024A1 (no)
AU (1) AU2007253302A1 (no)
CA (1) CA2652857A1 (no)
CL (1) CL2007001427A1 (no)
IL (1) IL195408A0 (no)
MX (1) MX2008014891A (no)
NO (1) NO20084882L (no)
PE (1) PE20080179A1 (no)
TW (1) TW200813081A (no)
WO (1) WO2007135134A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2019113A1 (en) * 2007-07-26 2009-01-28 Anadys Pharmaceuticals, Inc. New Crystalline Salts of 5-Amino-3-(2',3'-di-O-acetyl-beta-D-ribofuranosyl)-3H-thiazolo[4,5-d]pyrimidin-2-one
EA020659B1 (ru) 2008-04-23 2014-12-30 Джилид Сайэнс, Инк. 1'-замещённые карбануклеозидные аналоги для противовирусной терапии
MX2012003126A (es) 2009-09-21 2012-06-19 Gilead Sciences Inc Procesos e intermedios para la preparacion de analogos de 1'-carbonucleosidos sustituidos.
AP2013006665A0 (en) 2010-07-19 2013-01-31 Gilead Sciences Inc Methods for the preparation of diasteromerically pure phosphoramidate prodrugs
MX2013000744A (es) 2010-07-22 2013-03-07 Gilead Sciences Inc Metodos y compuestos para tratar infecciones virales por paramyxoviridae.
TWI767201B (zh) 2014-10-29 2022-06-11 美商基利科學股份有限公司 絲狀病毒科病毒感染之治療
CA2963717C (en) 2014-12-08 2023-10-10 F. Hoffmann-La Roche Ag 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds for the treatment and prophylaxis of virus infection
WO2016146598A1 (en) 2015-03-16 2016-09-22 F. Hoffmann-La Roche Ag Combined treatment with a tlr7 agonist and an hbv capsid assembly inhibitor
WO2016180691A1 (en) 2015-05-08 2016-11-17 F. Hoffmann-La Roche Ag Novel oxathiolane carboxylic acids and derivatives for the treatment and prophylaxis of virus infection
WO2016180743A1 (en) 2015-05-12 2016-11-17 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
WO2017001307A1 (en) 2015-06-30 2017-01-05 F. Hoffmann-La Roche Ag Novel substituted aminothiazolopyrimidinedione for the treatment and prophylaxis of virus infection
MA42819A (fr) 2015-09-16 2018-07-25 Gilead Sciences Inc Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
CA3048768A1 (en) 2017-01-06 2018-07-12 F. Hoffmann-La Roche Ag Process for the preparation of 3-substituted 5-amino-6h-thiazolo[4,5-d]pyrimidine-2,7-dione compounds
TW201836615A (zh) 2017-03-14 2018-10-16 美商基利科學股份有限公司 治療貓冠狀病毒感染之方法
AU2018262501B2 (en) 2017-05-01 2020-12-10 Gilead Sciences, Inc. Crystalline forms of (S) 2 ethylbutyl 2 (((S) (((2R,3S,4R,5R) 5 (4 aminopyrrolo[2,1-f] [1,2,4]triazin-7-yl)-5-cyano-3,4-dihydroxytetrahydrofuran-2 yl)methoxy)(phenoxy) phosphoryl)amino)propanoate
US10675296B2 (en) 2017-07-11 2020-06-09 Gilead Sciences, Inc. Compositions comprising an RNA polymerase inhibitor and cyclodextrin for treating viral infections
TWI789695B (zh) 2020-01-27 2023-01-11 美商基利科學股份有限公司 治療sars cov-2感染之方法
TWI785528B (zh) 2020-03-12 2022-12-01 美商基利科學股份有限公司 1’-氰基核苷之製備方法
EP4132651A1 (en) 2020-04-06 2023-02-15 Gilead Sciences, Inc. Inhalation formulations of 1'-cyano substituted carbanucleoside analogs
EP4157272A1 (en) 2020-05-29 2023-04-05 Gilead Sciences, Inc. Remdesivir treatment methods
BR112022026321A2 (pt) 2020-06-24 2023-01-17 Gilead Sciences Inc Análogos de 1'-ciano nucleosídeo e usos dos mesmos
US11926645B2 (en) 2020-08-27 2024-03-12 Gilead Sciences, Inc. Compounds and methods for treatment of viral infections
TW202400185A (zh) 2022-03-02 2024-01-01 美商基利科學股份有限公司 用於治療病毒感染的化合物及方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001078418A1 (de) * 2000-04-06 2001-10-18 Siemens Aktiengesellschaft Bereitstellen von ergäanzenden diensten in einem paketvermittelnden kommunikationsnetz
BR0214407A (pt) * 2001-11-27 2004-10-19 Anadys Pharmaceuticals Inc Compostos, composições farmacêuticas e método de modulação das imunoatividades da citocina
US7321033B2 (en) * 2001-11-27 2008-01-22 Anadys Pharmaceuticals, Inc. 3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
ATE465742T1 (de) * 2003-09-05 2010-05-15 Anadys Pharmaceuticals Inc Tlr7-liganden zur behandlung von hepatitis c
US20080070852A1 (en) * 2004-06-07 2008-03-20 Averett Devron R 3-Beta-D-Ribofuranosylthiazolo[ 4,5-D] Pyridimine Nucleosides and Uses Thereof

Also Published As

Publication number Publication date
TW200813081A (en) 2008-03-16
PE20080179A1 (es) 2008-04-22
IL195408A0 (en) 2011-08-01
CL2007001427A1 (es) 2008-05-16
JP2009537603A (ja) 2009-10-29
EP2027139A1 (en) 2009-02-25
CA2652857A1 (en) 2007-11-29
WO2007135134A1 (en) 2007-11-29
US20100286081A1 (en) 2010-11-11
KR20090029730A (ko) 2009-03-23
MX2008014891A (es) 2009-01-29
CN101528762A (zh) 2009-09-09
AU2007253302A1 (en) 2007-11-29
AR061024A1 (es) 2008-07-30

Similar Documents

Publication Publication Date Title
NO20084882L (no) Krystallinske former A og B av et maleatsalt av 5-amino-3-(2'3'-di-o-acetyl-beta-D-ribofuranosyl)-3H-tiazolo[4,5-d] pyrimidin-2 on
FR17C1013I2 (fr) Pyrrolo[2,3-b]pyridines et pyrrolo[2,3-b]pyrimidines a substitution heteroaryle en tant qu'inhibiteurs de la janus kinase
NO20071095L (no) Hittil ukjente tiofenderivater
WO2007044407A3 (en) Pyrazolo (1 , 5a) pyrimidines as protein kinase inhibitors
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
NO20054905D0 (no) 2-acylamino-4-fenyltiazolderivater, fremgangsmate for deres fremstilling og anvendelse av de samme som i terapeutika
NO20070723L (no) Progesteron reseptormodulatorer inneholdende pyrrol-oksindolderivater og deres anvendelse
WO2007058942A3 (en) Imidazopyrazines as protein kinase inhibitors
WO2005016528A3 (en) 6-substituted anilino purines as rtk inhibitors
CO5660287A2 (es) Derivados de tetrahidrocarbazol y su uso farmaceutico
TW200745127A (en) Pyrazolopyrimidines as protein kinase inhibitors
WO2007048065A3 (en) Pyrimidinones as casein kinase ii (ck2) modulators
UA96449C2 (en) Stable laquinimod preparations
PL377795A1 (pl) Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
WO2008076883A3 (en) Triazine derivatives and their therapeutical applications
NO20032909D0 (no) Glukopyranosyloksypyrazolderivater samt medikamentell anvendelse derav
DK2004641T3 (da) HIV-inhiberende 5-(hydroxymethylen og aminomethylen) substituerede pyrimidiner
NO20090348L (no) Substituerte imidazolonderivater, sammensetninger og anvendelser av samme, samt fremgangsmater for fremstilling av samme
ECSP055701A (es) Nuevos derivados de pirimidinamida y el uso de los mismos
DE502004002571D1 (de) Substituierte 3-pyrrolidin-indol-derivate
NO20062605L (no) Farmasoytisk formulering inneholdende smakssubstanser med forbedrede farmasoytiske egenskaper
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
DK1773796T3 (da) Oxopiperidinderivater, fremstilling deraf samt terapeutisk anvendelse deraf
DK1517890T3 (da) Kationisk substituerede diphenylazetidinoner, fremgangsmåde til deres fremstilling, lægemidler indeholdende disse forbindelser og deres anvendelse
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application